Skip to content
Review Open access

FGFR signaling and apoptotic regulation in cancer: links to immune evasion, therapeutic resistance, and treatment re-engagement

Sep 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 95 references
Medicine

TL;DR

A framework for mechanism-based treatment strategies in FGFR-aberrant cancers is provided by linking apoptotic regulation, immune evasion, and therapeutic resistance by linking apoptotic regulation, immune evasion, and therapeutic resistance.

Abstract

Fibroblast growth factor receptor (FGFR) signaling is a major oncogenic pathway in multiple cancer types and an important determinant of therapeutic response and resistance. However, its role in coordinating apoptotic susceptibility with tumor immune escape remains insufficiently integrated. This review summarizes how FGFR signaling regulates mitochondrial apoptosis through the RAS–RAF–MEK–ERK, PI3K–AKT–mTOR, PLCγ–PKC/Ca²+, and JAK–STAT pathways. These signaling networks converge on BCL-2 family proteins, BH3-only regulators, FOXO-dependent transcription, BAX/BAK activation, mitochondrial outer membrane permeabilization, cytochrome c release, and caspase activation. Non-canonical mechanisms involving redox homeostasis, metabolic stress, c-Myc regulation, and autophagy further determine whether FGFR inhibition produces transient adaptation or irreversible cell death. FGFR alterations may also shape the immune contexture of selected tumors by influencing inflammatory signaling, PD-L1 regulation, antigen-presentation pathways, tumor–stromal interactions, and susceptibility to immune-mediated elimination. These effects are strongly dependent on tumor lineage, genomic background, bypass receptor tyrosine kinase signaling, mitochondrial priming, and the local immune microenvironment. We further synthesize preclinical and emerging clinical evidence for combining FGFR-targeted therapies with immune checkpoint blockade and discuss the biomarkers and limitations that may determine therapeutic benefit. By linking apoptotic regulation, immune evasion, and therapeutic resistance, this review provides a framework for mechanism-based treatment strategies in FGFR-aberrant cancers.

Read PDF

Similar papers

Review Open access Sep 2026

PI3K/AKT/mTOR signaling at the immune checkpoint interface in lung cancer: molecular mechanisms, Tumor–Immune remodeling, therapeutic resistance, and emerging treatment strategies

Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have substantially improved the treatment of lung cancer, yet durable responses remain limited by primary and acquired resistance. Increasing evidence identifies the PI3K/AKT/mTOR pathway as a central link between oncogenic signaling, metabolic adaptation, and...

Hong-Liang Jin, Fan Yang, Shi Zong et al. · 0 citations
Review Open access 2026

Implications of KRAS in Molecular Signaling Pathways in Oral Squamous Cell Carcinoma: Interplay with Autophagy, Apoptosis, and Oxidative Stress

: Oral squamous cell carcinoma (OSCC) is an aggressive malignancy often diagnosed at advanced stages and associated with poor prognosis. This review aims to summarize the role of Kirsten rat sarcoma viral oncogene homolog (KRAS) signaling in OSCC progression, with particular emphasis on its involvement in the regulatio...

Bianca Voicu-Bălășea, Alexandra Popa, Florentina Rus et al. · 0 citations
Review Open access Nov 2026

Natural compounds regulating MAPK-related signaling pathways: potential intervention strategies for gastric cancer

Gastric cancer (GC) is a common malignant tumor of the digestive system, and its progression involves multiple molecular factors and signaling pathways. Dysregulation of mitogen-activated protein kinase (MAPK)-related signaling pathways is closely associated with the proliferation, invasion, metastasis, and drug resi...

Song Guo, Hong-Bao Wang, You Wang et al. · 0 citations
Review Open access Oct 2026

Hypoxia-Driven Extracellular Vesicle Signaling in Lung Cancer Progression, Immune Evasion, and Therapeutic Resistance

Targeting hypoxia-driven EV signaling may suppress tumor progression and improve treatment efficacy, and targeting EV biogenesis or transfer may also help overcome resistance to targeted therapy and immunotherapy.

Dordaneh Mirbabaei Ghafghazi, P. Klentrou, Siu-Kwan Sze et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.